(Phenylamino)pyrimidine-1,2,3-triazole derivatives as analogs of imatinib: searching for novel compounds against chronic myeloid leukemia

The enzyme tyrosine kinase BCR-Abl-1 is the main molecular target in the treatment of chronic myeloid leukemia and can be competitively inhibited by tyrosine kinase inhibitors such as imatinib. New potential competitive inhibitors were synthesized using the (phenylamino)pyrimidine-pyridine (PAPP) gr...

Full description

Saved in:

Bibliographic Details
Published in:	Beilstein journal of organic chemistry Vol. 17; no. 1; pp. 2260 - 2269
Main Authors:	Pimentel, Luiz Claudio Ferreira, Hoelz, Lucas Villas Boas, Canzian, Henayle Fernandes, Branco, Frederico Silva Castelo, de Oliveira, Andressa Paula, Campos, Vinicius Rangel, Júnior, Floriano Paes Silva, Dantas, Rafael Ferreira, Resende, Jackson Antônio Lamounier Camargos, Cunha, Anna Claudia, Boechat, Nubia, Bastos, Mônica Macedo
Format:	Journal Article
Language:	English
Published:	Germany Beilstein-Institut zur Föerderung der Chemischen Wissenschaften 01.09.2021 Beilstein-Institut
Subjects:	(phenylamino)pyrimidine-pyridine 1,2,3-triazole 1,3-dipolar cycloaddition BCR-ABL protein Binding sites Chemistry Chromosomes Chronic myeloid leukemia Confidence intervals Cytotoxicity Design Enzymes Full Research Paper Fusion protein Imatinib Kinases Leukemia Mutation Myeloid leukemia Protein-tyrosine kinase Triazoles (phenylamino)pyrimidine-pyridine chronic myeloid leukemia imatinib 1,2,3-triazole 1,3-dipolar cycloaddition
ISSN:	1860-5397, 2195-951X, 1860-5397
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!